Breast Care · 2018 · 19 citations · 23 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMetastasisBreast Cancer PharmacotherapyChemotherapy Toxicity ManagementCytotoxic ChemotherapyMetastatic Breast CancerMetastatic Cancer ManagementToxicity ManagementBreast Cancer ChemotherapyChemotherapy Dose-limiting ToxicityCyclophosphamide-based TherapyMetastatic Breast Cancer TreatmentMetastatic Site-specific TreatmentPrognostic Subgroup AnalysisSafety Subgroup AnalysisSerious Adverse Events
BACKGROUND: Low-dose metronomic chemotherapy (LDMC) is increasingly used in metastatic breast cancer (MBC). In this retrospective analysis, we examined the therapeutic effects and side effects of LDMC in a cohort of MBC patients. METHODS: Patients with MBC were included when LDMC with oral cyclophosphamide (CTX) and methotrexate (MTX) was administered between 2009 and 2015. The primary endpoint was disease control rate (DCR) ≥ 24 weeks after the start of LDMC. Secondary endpoints were duration of progression-free survival (PFS), rates of discontinuation due to side effects, and DCR with regard to subgroups. RESULTS: Retrospective data of 35 patients were available for this analysis. 31% patients achieved DCR. The median PFS was 12 weeks. 9% of patients discontinued LDMC due to adverse events. DCR was 37% in the first 2 lines and 25% in further lines of therapy. 22% of patients with multiple metastases and 35% with ≤2 different metastatic sites achieved DCR. DCR was achieved in 33% of hormone receptor(HR)-positive patients and 27% of HR-negative patients. CONCLUSION: The DCR of 31% is in line with the results of previous phase II studies. LDMC was well tolerated. Subgroup analysis was not able to identify a group in which LDMC was more efficient.
23
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +11
François Ghiringhelli, Cédric Menard, Pierre E. Puig et al. · Cancer Immunology Immunotherapy · 2006 · 1.2K citations · Full text
Life Sciences, Immunology, Oncology +17
Gabriel N. Hortobágyi · New England Journal of Medicine · 1998 · 781 citations
Marco Colleoni, Andrea Rocca, Maria Teresa Sandri et al. · Annals of Oncology · 2002 · 502 citations · Full text
Medicine, Oncology, Pharmacology +17